(Q46963955)

26 December 2017

title

Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives (English)

1 reference

26 December 2017

1 reference

1 reference

1 reference

1 reference

Barrera MV

1

1 reference

26 December 2017

Herrera E

series ordinal

2

1 reference

26 December 2017

publication date

1 October 2007

1 reference

26 December 2017

Actas Dermo-Sifiliográficas

published in

1 reference

26 December 2017

volume

98

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

page(s)

556-562

1 reference

26 December 2017

A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Topical treatment strategies for non-melanoma skin cancer and precursor lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Topical and light-based treatments for actinic keratoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Topical diclofenac in hyaluronan gel for the treatment of solar keratoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Current and novel treatment options for actinic keratosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-7310%2807%2970133-3

10.1016/S0001-7310(07)70133-3

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017